Filing Details
- Accession Number:
- 0000899243-20-004522
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-13 18:30:38
- Reporting Period:
- 2020-02-11
- Accepted Time:
- 2020-02-13 18:30:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1367644 | Emergent Biosolutions Inc. | EBS | Pharmaceutical Preparations (2834) | 141902018 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1380185 | Fuad El-Hibri | 400 Professional Drive, Suite 400 Gaithersburg MD 20879 | Chairman | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-11 | 6,280 | $25.62 | 1,485,298 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-11 | 6,280 | $62.90 | 1,479,018 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-02-12 | 13,720 | $25.62 | 1,492,738 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-12 | 13,720 | $62.90 | 1,479,018 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Options (Right to Buy) | Disposition | 2020-02-11 | 6,280 | $0.00 | 6,280 | $25.62 |
| Common Stock | Employee Stock Options (Right to Buy) | Disposition | 2020-02-12 | 13,720 | $0.00 | 13,720 | $25.62 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 57,038 | 2021-03-10 | No | 4 | M | Direct | |
| 43,318 | 2021-03-10 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 4,344,250 | Indirect | By Intervac, L.L.C. |
| Common Stock | 1,524,155 | Indirect | By Biovac, L.L.C. |
Footnotes
- All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934.
- Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
- Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
- The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017.
Billionaire Hedge Funds
